Slide

Abstracts and Publications

Abstracts and Publications

Initial Data From Phase 12 Clinical Trial of AU-007 Show Trend in Decreasing Tregs
Initial results from dose escalation of a phase 1/2, first-in-human, open label study of AU-007, a monoclonal antibody that binds to IL-2 and prevents its binding to CD25, in patients with solid tumors

Vasselli J, De Souza P, Frentzas S, et al.

Poster presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 2022

AULOS ASCO 2022 Poster
Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors

Vasselli J, De Souza P, Frentzas S, et al.

Poster presentation at the American Society of Clinical Oncology (ASCO), June 2022

Preclinical Data Poster
AU-007, a computationally designed human antibody to the CD25-interacting domain of IL-2, demonstrates strong activity in murine syngeneic tumors in combination with IL-2 and PD-1 or PD-L1 antibodies

Amit I, Levin I, Wyant T, et al.

Preclinical poster, March 2022

AULOS SITC 2021 AU-007 Preclinical Data Poster FINAL
AU-007, a computationally designed human antibody, mediates human immune activation by endogenous IL-2, while uniquely breaking the IL-2 negative feedback loop and preventing Treg expansion

Amit I, Levin I, Wyant T, et al.

Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 2021

Computationally Designed Antibodies Unlocking the Body’s Own IL-2 to Fight Cancer

Yanay Ofran, Ph.D.

Poster presentation video at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 2021

AU-007

AU-007’s unique mechanism of action achieves what no other IL-2 therapeutic in development does – tips the balance toward immune activation and away from immune suppression.

LEARN MORE →